30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Results from a 3-year extension of the Phase 3 SUMMIT study treating articular cartilage defects with Vericel's MACI™ (matrix-applied characterized autologous cultured chondrocytes) indicate that treatment was clinically and statistically significantly better than microfracture, with similar structural repair tissue and safety. (Vericel Corporation, 3/25/15)